Mammaglobin expression in the female genital tract: Immunohistochemical analysis in benign and neoplastic endocervix and endometrium

International Journal of Gynecological Pathology

Volumn 27, Issue 3, 2008, Pages 418-425

  Onuma, Kazuya ^a,b   Dabbs, David J ^a   Bhargava, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Endocervix; Endometrium; Mammaglogin

Indexed keywords

HORMONE RECEPTOR; MAMMAGLOBIN; TUMOR MARKER; TUMOR PROTEIN; UTEROGLOBIN;

ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; ADENOCARCINOMA; BIOSYNTHESIS; CARCINOMA IN SITU; ENDOMETRIUM; ENDOMETRIUM TUMOR; METABOLISM; UTERINE CERVIX; UTERINE CERVIX TUMOR; UTERUS; UTERUS CANCER;

ADENOCARCINOMA; CARCINOMA IN SITU; CERVIX UTERI; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS; UTEROGLOBIN; UTERUS;

EID: 49549112326     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31815d05ec     Document Type: Article

References (32)

1. Beier HM, Bernard A, Cqhilton BS, et al. Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report. Ann NY Acad Sci 2000;923:348-354 (Pubitemid 32050234)
2. Miele L, Cordella-Miele E, Mukherjee AB. Uteroglobin: structure, molecular biology, and new perspectives on its function as a phospholipase A2 inhibitor. Endocr Rev 1987;8:474-490
3. Parker MG, White R, Hurst H, et al. Prostatic steroid binding protein. Isolation and characterization of C3 genes. J Biol Chem 1983;258:12-15 (Pubitemid 13165794)
4. Peri A, Cordella-Miele E, Miele L, et al. Tissue specific expression of the gene coding for human Clara cell 10-kD protein, phospholipase A2-inhibitory protein. J Clin Invest 1993;92:2099-2109 (Pubitemid 23333512)
5. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996;56:860-865
6. Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999;59:3028-3031 (Pubitemid 29315994)
7. Grunewald K, Haun M, Fiegl M, et al. Mammaglobin expression gynecologic malignancies and malignant effusions detected by nested reverse transcriptase-polymerase chain reaction. Lab Invest 2002;82:1147-1153 (Pubitemid 35014848)
8. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127:103-113 (Pubitemid 46797025)
9. Watson MA, Darrow C, Zimonjic DB, et al. Structures and transcriptional regulation of the human mammaglobin gene, breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13. Oncogene 1998;16:817-824 (Pubitemid 28076094)
10. Zach O, Kasparu H, Krieger O, et al. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction for mammaglobin mRNA. J Clin Oncol 1999;17:2015-2019 (Pubitemid 29318829)
11. O'Brien N, Maguire TM, O'Donovan N, et al. Mammaglobin A: a promising marker for breast cancer. Clin Chem 2002;48:1362-1364 (Pubitemid 34809847)
12. Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 2004;37:249-257 (Pubitemid 38314877)
13. Sjodin A, Guo D, Hofer PA, et al. Mammaglobin in normal human sweat glands and human sweat gland tumors. J Invest Dermatol 2003;121:428-429 (Pubitemid 36969920)
14. Zafrakas M, Petschke B, Donner A, et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006;6:88. (Pubitemid 44082101)
15. Sasaki E, Tsunoda N, Hatanaka Y, et al. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007;20:208-214 (Pubitemid 46422175)
16. Leygue E, Snell L, Dotzlaw H, et al. Mammablobin, a potential marker of breast cancer nodal metastasis. J Pathol 1999;189:28-33. (Pubitemid 29406815)
17. Nunez-Villar MJ, Martinez-Arribas F, Pollan M, et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 2003;5:R65-R70.
18. Span PN, Waanders E, Manders P, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol 2004;22:691-698 (Pubitemid 41095073)
19. Carcangiu ML, Chambers JT, Voynick IM, et al. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol 1990;94:247-254 (Pubitemid 20275337)
20. Segreti EM, Novotny DB, Soper JT, et al. Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol 1989;73:780-784
21. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas. A clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004;28:1568-1578 (Pubitemid 39564961)
22. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-223
23. Lax SF, Kendell B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-824 (Pubitemid 30091101)
24. Kovalev S, Marchenko ND, Gugliotta BG, et al. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol 1998;29:613-619 (Pubitemid 28272717)
25. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274
26. Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol 1999;27:172-177
27. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2001;21:11-15
28. Kamoi S, Al Juboury MI, Akin MR, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: Another viewpoint. Int J Gynecol Pathol 2003;21:217-223 (Pubitemid 34680337)
29. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: Immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28:160-167 (Pubitemid 38124723)
30. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949
31. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarray for high-throughput molecular profiling of tumor specimen. Nat Med 1998;4:844-847 (Pubitemid 28331029)
32. Bhargava R, Lal P, Chen B. Feasibility of using tissue microarray for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol 2004;13:213-216 (Pubitemid 39552242)